Impact outcomes (detection of new infections/uptake/turnaround time/linkage to care) associated with the use of rapid multiplexed STI diagnostic devices
| Author, year | Impact outcome | Multiplex test type | Result |
| Pai et al, 201419 | New infection | IMT | 1/109 (0.9%) new infection of syphilis and 1/109 (0.9%) new infection of HIV detected with IMT |
| Pai et al, 2014*19 | New infection | IMT | 56/375 (14.9%) diagnosed with HIV, 75/375 (20.0%) with HBV, (37/375) 9.9% with syphilis, 2/375 (0.5%) with HCV |
| Pant Pai, et al 201921 | New infection | IMT | 30/510 (5.9%) new infections of HBV and 11/510 (2.2%) new infections of TV detected with IMT |
| Van Der Pol et al, 2017†29 | New infection | Molecular assay | 3.2% more infections of TV detected by molecular assay than culture and 71.4% more than wet mount |
| Pant Pai et al, 201921 | Uptake | IMT | 99.4% increase for HCV IMT 79.0% increase for HBV IMT 42.0% increase for HIV IMT 99.6% increase for TV IMT |
| Le Roy et al, 201223 | TAT | Molecular assay | 4.5–5 hours for 50 samples (CT) |
| Longo et al, 201824 | TAT | IMT | 15 min (HIV, HBV and HCV) |
| Mboumba Bouassa et al, 201825 | TAT | IMT | 15 min (HIV, HBV, HCV) |
| Nuñez-Forero et al, 201626 | TAT | Molecular assay | 14 min (CT and NG) |
| Omoding et al, 201427 | TAT | IMT | 20 min (syphilis and HIV) |
| Causer et al, 201522 | TAT | Molecular assay | 91 min (CT and NG) |
| Pant Pai et al, 201921 | Retention in care | IMT | 95.0% patients retained in care (HIV, HBV, HCV, TV) |
| Pant Pai et al, 201921 | Linkage to care | IMT | 70.0% patients linked to care (HIV, HBV, HCV, TV) |
| Kalla et al, 201928 | Linkage to care | IMT | 100.0% patients linked to care (HIV, HBV, HCV) |
| Menzato et al, 201818 | Linkage to care | IMT | 100.0% patients linked to care (HIV) |
*Study conducted in Canadian and Indian populations.
†Raw data were unavailable in the publication.
CT, Chlamydia trachomatis; HBV, hepatitis B virus; HCV, hepatitis C virus; IMT, immunochromatographic test; NG, Neisseria gonorrhoeae; STI, sexually transmitted infection; TAT, turnaround time; TV, Trichomonas vaginalis.